{"id":878,"date":"2026-03-12T17:26:35","date_gmt":"2026-03-12T16:26:35","guid":{"rendered":"https:\/\/biotechlerncenter.iph-multisite.berta-bewegt.ch\/?page_id=878"},"modified":"2026-03-12T17:26:35","modified_gmt":"2026-03-12T16:26:35","slug":"7-utilisation-observation-developpement-ulterieur-phase-iv","status":"publish","type":"page","link":"https:\/\/biotechlerncenter.iph-multisite.berta-bewegt.ch\/fr\/sujets\/genese-dun-medicament\/7-utilisation-observation-developpement-ulterieur-phase-iv\/","title":{"rendered":"7. Utilisation, observation, d\u00e9veloppement ult\u00e9rieur: phase IV"},"content":{"rendered":"\n

Une fois le m\u00e9dicament homologu\u00e9, il peut \u00eatre prescrit par des m\u00e9decins et b\u00e9n\u00e9ficie aux patients concern\u00e9s. M\u00e9decins, fabricants et autorit\u00e9s de contr\u00f4le des m\u00e9dicaments veillent \u00e0 l’apparition d’\u00e9ventuels effets ind\u00e9sirables rares. Des effets ind\u00e9sirables extr\u00eamement rares – n’apparaissant par exemple que chez un patient sur 10’000 – ne peuvent \u00eatre identifi\u00e9s qu’\u00e0 partir du moment o\u00f9 un tr\u00e8s grand nombre de patients prennent le m\u00e9dicament. C’est pourquoi l’on proc\u00e8de aussi \u00e0 ce que l’on appelle des \u00e9tudes d’utilisation, qui soumettent un m\u00e9dicament \u00e0 l’\u00e9preuve de la r\u00e9alit\u00e9 quotidienne. L’information \u00e0 l’intention des patients – la notice d’utilisation – est d\u00e9sormais adapt\u00e9e en permanence aux nouvelles connaissances. Les \u00e9tudes de phase IV peuvent durer des ann\u00e9es. Mais les r\u00e9sultats de ces \u00e9tudes peuvent aussi contribuer \u00e0 \u00e9largir l’\u00e9ventail de traitement du principe actif : une mol\u00e9cule con\u00e7ue pour combattre une certaine forme de cancer peut par exemple s’av\u00e9rer \u00e9galement efficace contre une forme apparent\u00e9e de la maladie. Dans ce cas, de nouvelles \u00e9tudes cliniques sont toutefois n\u00e9cessaires.<\/p>\n","protected":false},"excerpt":{"rendered":"

Une fois le m\u00e9dicament homologu\u00e9, il peut \u00eatre prescrit par des m\u00e9decins et b\u00e9n\u00e9ficie aux patients concern\u00e9s. M\u00e9decins, fabricants et autorit\u00e9s de contr\u00f4le des m\u00e9dicaments veillent \u00e0 l’apparition d’\u00e9ventuels effets ind\u00e9sirables rares. Des effets ind\u00e9sirables extr\u00eamement rares – n’apparaissant par exemple que chez un patient sur 10’000 – ne peuvent \u00eatre identifi\u00e9s qu’\u00e0 partir du […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":898,"menu_order":6,"comment_status":"closed","ping_status":"closed","template":"page-templates\/unterthema.php","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"class_list":["post-878","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\n7. Utilisation, observation, d\u00e9veloppement ult\u00e9rieur: phase IV - biotechlerncenter<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"7. Utilisation, observation, d\u00e9veloppement ult\u00e9rieur: phase IV - biotechlerncenter\" \/>\n<meta property=\"og:description\" content=\"Une fois le m\u00e9dicament homologu\u00e9, il peut \u00eatre prescrit par des m\u00e9decins et b\u00e9n\u00e9ficie aux patients concern\u00e9s. M\u00e9decins, fabricants et autorit\u00e9s de contr\u00f4le des m\u00e9dicaments veillent \u00e0 l’apparition d’\u00e9ventuels effets ind\u00e9sirables rares. Des effets ind\u00e9sirables extr\u00eamement rares – n’apparaissant par exemple que chez un patient sur 10’000 – ne peuvent \u00eatre identifi\u00e9s qu’\u00e0 partir du […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/biotechlerncenter.iph-multisite.berta-bewegt.ch\/fr\/sujets\/genese-dun-medicament\/7-utilisation-observation-developpement-ulterieur-phase-iv\/\" \/>\n<meta property=\"og:site_name\" content=\"biotechlerncenter\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/biotechlerncenter.iph-multisite.berta-bewegt.ch\/fr\/sujets\/genese-dun-medicament\/7-utilisation-observation-developpement-ulterieur-phase-iv\/\",\"url\":\"https:\/\/biotechlerncenter.iph-multisite.berta-bewegt.ch\/fr\/sujets\/genese-dun-medicament\/7-utilisation-observation-developpement-ulterieur-phase-iv\/\",\"name\":\"7. Utilisation, observation, d\u00e9veloppement ult\u00e9rieur: phase IV - biotechlerncenter\",\"isPartOf\":{\"@id\":\"https:\/\/biotechlerncenter.iph-multisite.berta-bewegt.ch\/#website\"},\"datePublished\":\"2026-03-12T16:26:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/biotechlerncenter.iph-multisite.berta-bewegt.ch\/fr\/sujets\/genese-dun-medicament\/7-utilisation-observation-developpement-ulterieur-phase-iv\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/biotechlerncenter.iph-multisite.berta-bewegt.ch\/fr\/sujets\/genese-dun-medicament\/7-utilisation-observation-developpement-ulterieur-phase-iv\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/biotechlerncenter.iph-multisite.berta-bewegt.ch\/fr\/sujets\/genese-dun-medicament\/7-utilisation-observation-developpement-ulterieur-phase-iv\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\/\/biotechlerncenter.iph-multisite.berta-bewegt.ch\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sujets\",\"item\":\"https:\/\/biotechlerncenter.iph-multisite.berta-bewegt.ch\/fr\/sujets\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Gen\u00e8se d’un m\u00e9dicament\",\"item\":\"https:\/\/biotechlerncenter.iph-multisite.berta-bewegt.ch\/fr\/sujets\/genese-dun-medicament\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"7. Utilisation, observation, d\u00e9veloppement ult\u00e9rieur: phase IV\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/biotechlerncenter.iph-multisite.berta-bewegt.ch\/#website\",\"url\":\"https:\/\/biotechlerncenter.iph-multisite.berta-bewegt.ch\/\",\"name\":\"biotechlerncenter\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/biotechlerncenter.iph-multisite.berta-bewegt.ch\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"7. Utilisation, observation, d\u00e9veloppement ult\u00e9rieur: phase IV - biotechlerncenter","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"7. Utilisation, observation, d\u00e9veloppement ult\u00e9rieur: phase IV - biotechlerncenter","og_description":"Une fois le m\u00e9dicament homologu\u00e9, il peut \u00eatre prescrit par des m\u00e9decins et b\u00e9n\u00e9ficie aux patients concern\u00e9s. M\u00e9decins, fabricants et autorit\u00e9s de contr\u00f4le des m\u00e9dicaments veillent \u00e0 l’apparition d’\u00e9ventuels effets ind\u00e9sirables rares. Des effets ind\u00e9sirables extr\u00eamement rares – n’apparaissant par exemple que chez un patient sur 10’000 – ne peuvent \u00eatre identifi\u00e9s qu’\u00e0 partir du […]","og_url":"https:\/\/biotechlerncenter.iph-multisite.berta-bewegt.ch\/fr\/sujets\/genese-dun-medicament\/7-utilisation-observation-developpement-ulterieur-phase-iv\/","og_site_name":"biotechlerncenter","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/biotechlerncenter.iph-multisite.berta-bewegt.ch\/fr\/sujets\/genese-dun-medicament\/7-utilisation-observation-developpement-ulterieur-phase-iv\/","url":"https:\/\/biotechlerncenter.iph-multisite.berta-bewegt.ch\/fr\/sujets\/genese-dun-medicament\/7-utilisation-observation-developpement-ulterieur-phase-iv\/","name":"7. Utilisation, observation, d\u00e9veloppement ult\u00e9rieur: phase IV - biotechlerncenter","isPartOf":{"@id":"https:\/\/biotechlerncenter.iph-multisite.berta-bewegt.ch\/#website"},"datePublished":"2026-03-12T16:26:35+00:00","breadcrumb":{"@id":"https:\/\/biotechlerncenter.iph-multisite.berta-bewegt.ch\/fr\/sujets\/genese-dun-medicament\/7-utilisation-observation-developpement-ulterieur-phase-iv\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/biotechlerncenter.iph-multisite.berta-bewegt.ch\/fr\/sujets\/genese-dun-medicament\/7-utilisation-observation-developpement-ulterieur-phase-iv\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/biotechlerncenter.iph-multisite.berta-bewegt.ch\/fr\/sujets\/genese-dun-medicament\/7-utilisation-observation-developpement-ulterieur-phase-iv\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/biotechlerncenter.iph-multisite.berta-bewegt.ch\/fr\/"},{"@type":"ListItem","position":2,"name":"Sujets","item":"https:\/\/biotechlerncenter.iph-multisite.berta-bewegt.ch\/fr\/sujets\/"},{"@type":"ListItem","position":3,"name":"Gen\u00e8se d’un m\u00e9dicament","item":"https:\/\/biotechlerncenter.iph-multisite.berta-bewegt.ch\/fr\/sujets\/genese-dun-medicament\/"},{"@type":"ListItem","position":4,"name":"7. Utilisation, observation, d\u00e9veloppement ult\u00e9rieur: phase IV"}]},{"@type":"WebSite","@id":"https:\/\/biotechlerncenter.iph-multisite.berta-bewegt.ch\/#website","url":"https:\/\/biotechlerncenter.iph-multisite.berta-bewegt.ch\/","name":"biotechlerncenter","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/biotechlerncenter.iph-multisite.berta-bewegt.ch\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"}]}},"_links":{"self":[{"href":"https:\/\/biotechlerncenter.iph-multisite.berta-bewegt.ch\/fr\/wp-json\/wp\/v2\/pages\/878","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/biotechlerncenter.iph-multisite.berta-bewegt.ch\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/biotechlerncenter.iph-multisite.berta-bewegt.ch\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/biotechlerncenter.iph-multisite.berta-bewegt.ch\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/biotechlerncenter.iph-multisite.berta-bewegt.ch\/fr\/wp-json\/wp\/v2\/comments?post=878"}],"version-history":[{"count":1,"href":"https:\/\/biotechlerncenter.iph-multisite.berta-bewegt.ch\/fr\/wp-json\/wp\/v2\/pages\/878\/revisions"}],"predecessor-version":[{"id":879,"href":"https:\/\/biotechlerncenter.iph-multisite.berta-bewegt.ch\/fr\/wp-json\/wp\/v2\/pages\/878\/revisions\/879"}],"up":[{"embeddable":true,"href":"https:\/\/biotechlerncenter.iph-multisite.berta-bewegt.ch\/fr\/wp-json\/wp\/v2\/pages\/898"}],"wp:attachment":[{"href":"https:\/\/biotechlerncenter.iph-multisite.berta-bewegt.ch\/fr\/wp-json\/wp\/v2\/media?parent=878"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}